Actinium Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2025 | FY2023 | FY2022 | FY2021 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|
| Revenue | $90.0K | $81.0K | $1.0M | $1.1M | $0 | $0 |
| Cost of Revenue | — | — | — | $900.0K | $0 | $0 |
| Gross Profit | — | — | — | $244.0K | $0 | $0 |
| Gross Margin | — | — | — | 21.3% | — | — |
| Operating Expenses | ||||||
| Research & Development | $21.1M | $38.7M | $23.1M | $18.0M | $323.8K | — |
| SG&A Expense | $15.2M | $13.3M | $12.0M | $8.1M | $3.0M | — |
| Operating Income | $-36.2M | $-51.9M | $-34.1M | $-25.0M | $-3.3M | $-26.1K |
| Operating Margin | -40,274.4% | -64,098.8% | -3,311.1% | -2,182.2% | — | — |
| Interest Expense | — | — | — | — | $-175.1K | $-6.4K |
| Pretax Income | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | $0 | $-834 |
| Net Income | $-33.9M | $-48.8M | $-33.0M | $-24.8M | $-3.4M | $-467.3K |
| Net Margin | -37,652.2% | -60,269.1% | -3,205.5% | -2,165.6% | — | — |
| EPS (Basic) | $-1.09 | $-1.83 | $-1.37 | $-1.20 | $-4.30 | $0.01 |
| EPS (Diluted) | $-1.09 | $-1.83 | $-1.37 | $-1.20 | $-4.30 | $0.01 |
| Shares Outstanding (Basic) | 31.2M | 26.6M | 24.1M | 20.6M | 13.7M | 11.2M |
| Shares Outstanding (Diluted) | 31.2M | 26.6M | 24.1M | 20.6M | 13.7M | 11.2M |
| Dividends Per Share | — | — | — | — | — | — |